A Prospective Study of Transsulfuration Biomarkers in Autistic Disorders
- 395 Downloads
The goal of this study was to evaluate transsulfuration metabolites in participants diagnosed with autism spectrum disorders (ASDs). Transsulfuration metabolites, including: plasma reduced glutathione (GSH), plasma oxidized glutathione (GSSG), plasma cysteine, plasma taurine, plasma sulfate, and plasma free sulfate among participants diagnosed with ASDs (n = 38) in comparison to age-matched neurotypical controls were prospectively evaluated. Testing was conducted using Vitamin Diagnostics, Inc. (CLIA-approved). Participants diagnosed with ASDs had significantly (P < 0.001) decreased plasma reduced GSH, plasma cysteine, plasma taurine, plasma sulfate, and plasma free sulfate relative to controls. By contrast, participants diagnosed with ASDs had significantly (P < 0.001) increased plasma GSSG relative to controls. The present observations are compatible with increased oxidative stress and a decreased detoxification capacity, particularly of mercury, in patients diagnosed with ASDs. Patients diagnosed with ASDs should be routinely tested to evaluate transsulfuration metabolites, and potential treatment protocols should be evaluated to potentially correct the transsulfuration abnormalities observed.
KeywordsHeavy metal Metabolic endophenotype Sulfation Sulfur
The authors wish to acknowledge the generous help of Brandon Work at LabCorp, Dallas and the phlebotomists at Medical Center Plano, Outpatient Phlebotomy. The authors wish to acknowledge the help of the parents and children who participated in the study; without their participation this type of investigation would not be possible. Study Funding: This research was funded by a grant from the Autism Research Institute, non-profit CoMeD, Inc., and by the non-profit Institute of Chronic Illnesses, Inc., through a grant from the Brenen Hornstein Autism Research & Education (BHARE) Foundation.
- 1.Autism and Developmental Disabilities Monitoring Network Surveillance Year 2002 Principal Investigators; Centers for Disease Control and Prevention (2007) Prevalence of autism spectrum disorders-autism and developmental disabilities monitoring network, 13 sites, United States, 2002. MMWR Surveill Summ 56(1):12–28Google Scholar
- 3.White JF (2003) Intestinal pathophysiology in autism. Exp Biol Med (Maywood) 228(6):639–649Google Scholar